Crizotinib-induced acute hepatitis: First case with relapse after reintroduction with reduced dose

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 1, 2013, Pages

  Ripault, Marie Pierre ^a   Pinzani, Véronique ^b   Fayolle, Véronique ^b   Pageaux, Georges Philippe ^a   Larrey, Dominique ^a,c  

^a HÔPITAL SAINT ELOI   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; CRIZOTINIB;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CANCER RECURRENCE; CASE REPORT; DRUG DOSE REDUCTION; DRUG RECHALLENGE; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; SIDE EFFECT; TRANSITIONAL BLINDNESS;

ACUTE DISEASE; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECURRENCE;

EID: 84873174416     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2012.10.003     Document Type: Article

References (16)

1. Kwak E.L., Bang Y.-J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
2. Sai-Hong Ignatius Ou. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Dev Ther 2011, 5:471-485.
3. Crino L., Kim D., Riely G.J., et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011, 15 suppl. [7514].
4. Camidge DR, Bang Y-J, Kwak EL, laffrate JA, Varella-Garcia M, Fox SB, Riely GJ, Salomon B, Ou SAIKim D-W, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. www.thelancet.com/oncology 2012;htpp://dx.doi.org/10.1016/S1470-2045(12)70344-3.
5. Forde P.M., Rudin C.M. Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother 2012, 13:1195-1201.
6. Ansm.sante.fr.
7. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Sem Liv Dis 2002, 22:145-155.
8. Fontana R.J., Watkins P.B., Bonkowsky H.L., Chalasani N., Davern T., Serrano J., et al. Rationale, design and conduct of drug induced liver injury network prospective study. Drug Saf 2009, 32:55-68.
9. Fontana R.J., Seef L.B., Andrade R.J., Bjornsson E., Day C.P., Serrano J., et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010, 52:730-742.
10. Aithal G.P., Watkins P.B., Andrade R.J., Larrey D., Molokhia M., Takikawa H., et al. Case definition and phenotype standardisation in drug-induced liver injury (DILI). Clin Pharmacol Ther 2011, 89:806-815.
11. Watkins P.B., Desai M., Berkowitch S.D., Peters G., Horsmans Y., Larrey D., et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011, 34:243-252.
12. Danan G., Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993, 46:1331-1336.
13. Benichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drug - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993, 46:1331-1336.
14. Tan W., Wilner K.D., Bang Y., et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple doses to advanced cancer patients. J Clin Oncol 2010, 28 suppl. [2596].
15. Pessayre O., Larrey D., Biour M. Drug-induced Liver injury. Oxford Textbook of Clinical Hepatology 1999, 2:1261-1315. Oxford University Press, Oxford. 2nd ed.
16. Larrey D., Tinel M., Letteron P., Maurel P., Loeper J., Belghiti J., et al. Metabolic activation of the new tricyclic antidepressant tianeptine by human liver cytochrome P450. Biochem Pharmacol 1990, 40:545-550.